Truist raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $220 from $205 and keeps a Buy rating on the shares following “positive” HERIZON-GEA-01 topline data. Current indications alone could drive Ziihera peaks sales greater than $2B, according to the firm. However, given breadth of HER2+ cancers for which Herceptin/Enhertu are standard of care, Truist thinks there’s plenty of upside from Ziihera, which the firm views as pipeline-in-a drug.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAZZ:
- Jazz Pharmaceuticals price target raised to $209 from $160 at Baird
- Jazz Pharmaceuticals price target raised to $247 from $230 at BofA
- Jazz Pharmaceuticals price target raised to $235 from $170 at Wells Fargo
- Jazz Pharmaceuticals’ Promising Pipeline and Strong Trial Results Lead to Buy Rating and Raised Price Objective
- Zymeworks Stock (ZYME) Soars on Positive Results for Cancer Drug Ziihera, Top Analysts Boost Price Targets